News & Views

Telix today announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Company (Lilly). Telix has demonstrated proof-of-concept (PoC) of using olaratumab to selectively deliver both diagnostic and therapeutic radiation to tumours as a radiopharmaceutical moiety and has produced a candidate for clinical translation. Telix will now progress to first-in-human clinical studies based on these highly encouraging results.

Telix today announces the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a Phase I study of TLX101 investigational therapy (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in Chinese patients with newly diagnosed glioblastoma (GBM).

Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 31 March 2023 on Monday 17 April 2023 at market close.

Telix today announces its financial results for the financial year ended 31 December 2022.

Telix today advises it will release its Full Year Results and Annual Report for the period ended 31 December 2022 on Monday 27 February 2023 at market close.

Telix advises that Associate Professor Brian Shuch, MD, Director, Kidney Cancer Program, UCLA Institute of Urologic Oncology (Los Angeles, California) and a Principal Investigator in the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) will be delivering an oral abstract presentation to the 2023 ASCO GU Symposium being held in San Francisco, CA, on Saturday 18 February at 2.00pm – 2.10pm PDT as the first presentation in the Renal and Rare Tumors session.

Telix today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December 2022 (Q4 2022). All figures are in AUD$ unless otherwise stated1 and provided on an unaudited basis.

Telix today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9–12 January) in San Francisco. As part of the Company’s presentation (lodged with this announcement), Telix has elected to disclose an unaudited revenue update for Q4 2022, reporting revenue of AU$76.8M (US$50.5M) generated from sales of Illuccix® kit for prostate cancer imaging in the United States (U.S.). This is an increase of 39% on Q3 2022, and a total of AU$149.7M (US$100.4M) revenue since Illuccix launch. ASCO GU, the leading specialised event for GU cancer care worldwide, will be the forum at which the Company will present the complete results of the ZIRCON trial in detail, including all trial primary and secondary end-points as well as specific grading criteria related to lesion size and detection.

Telix today announces that the completed pivotal Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) has been selected for oral presentation at the upcoming 2023 ASCO GU Symposium to be held in San Francisco, CA, from February 16-18 2023.   ASCO GU, the leading specialised event for GU cancer care worldwide, will be the forum at which the Company will present the complete results of the ZIRCON trial in detail, including all trial primary and secondary end-points as well as specific grading criteria related to lesion size and detection.

Telix today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning.